Rosalyn Blumenthal

Summary

Affiliation: Garden State Cancer Center
Country: USA

Publications

  1. ncbi Technology evaluation: cT84.66, City of Hope
    Rosalyn D Blumenthal
    Garden State Cancer Center, 520 Belleville Avenue, Belleville, NJ 07109, USA
    Curr Opin Mol Ther 6:90-5. 2004
  2. ncbi Technology evaluation: Onyvax-105, Onyvax
    Rosalyn D Blumenthal
    Garden State Cancer Center, 520 Belleville Avenue, Belleville, NJ 07109, USA
    Curr Opin Mol Ther 5:668-72. 2003
  3. ncbi Methods and goals for the use of in vitro and in vivo chemosensitivity testing
    Rosalyn D Blumenthal
    Garden State Cancer Center, Belleville, NJ 07109, USA
    Mol Biotechnol 35:185-97. 2007
  4. ncbi Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers
    Rosalyn D Blumenthal
    Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ 07109, USA
    BMC Cancer 7:2. 2007
  5. ncbi Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (Carcinoembryonic Antigen)
    Rosalyn D Blumenthal
    Center for Molecular Medicine and Immunology, Garden State Cancer Center, Belleville, New Jersey 07109, USA
    Cancer Res 65:8809-17. 2005
  6. ncbi Abnormal expression of the angiopoietins and Tie receptors in menorrhagic endometrium
    Rosalyn D Blumenthal
    Garden State Cancer Center, Belleville, New Jersey 07109, USA
    Fertil Steril 78:1294-300. 2002
  7. ncbi Tumor-specific dose scheduling of bimodal radioimmunotherapy and chemotherapy
    R D Blumenthal
    Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ 07109, USA
    Anticancer Res 23:4613-9. 2003
  8. ncbi An in vitro model to optimize dose scheduling of multimodal radioimmunotherapy and chemotherapy: effects of p53 expression
    Rosalyn D Blumenthal
    Garden State Cancer Center, Belleville, NJ 07109, USA
    Int J Cancer 108:293-300. 2004
  9. ncbi Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer
    Thomas M Cardillo
    The Garden State Cancer Center, 520 Belleville Avenue, Belleville, NJ 07109, USA
    Int J Cancer 97:386-92. 2002
  10. ncbi Advantage of combining NLCQ-1 (NSC 709257) with radiation in treatment of human head and neck xenografts
    Maria V Papadopoulou
    Department of Radiation Medicine, Evanston Northwestern Healthcare, Evanston, Illinois 60201, USA
    Radiat Res 168:65-71. 2007

Research Grants

  1. PRE-CLINICAL COMBINATION CHEMO- AND RADIOANTIBODY THERAP
    Rosalyn Blumenthal; Fiscal Year: 2004

Detail Information

Publications20

  1. ncbi Technology evaluation: cT84.66, City of Hope
    Rosalyn D Blumenthal
    Garden State Cancer Center, 520 Belleville Avenue, Belleville, NJ 07109, USA
    Curr Opin Mol Ther 6:90-5. 2004
    ..Chimeric T84.66 (cT84.66) is a high affinity anti-carcinoembryonic antigen (CEA) immunoglobulin G1, that is being developed by City of Hope for the potential treatment of CEA-expressing malignancies...
  2. ncbi Technology evaluation: Onyvax-105, Onyvax
    Rosalyn D Blumenthal
    Garden State Cancer Center, 520 Belleville Avenue, Belleville, NJ 07109, USA
    Curr Opin Mol Ther 5:668-72. 2003
    ..Onyvax, under license from the Cancer Research Campaign, is developing Onyvax-105 (105AD7), an anti-idiotype monoclonal antibody, for the potential treatment of colorectal cancer. Onyvax initiated phase II clinical trials in May 2000...
  3. ncbi Methods and goals for the use of in vitro and in vivo chemosensitivity testing
    Rosalyn D Blumenthal
    Garden State Cancer Center, Belleville, NJ 07109, USA
    Mol Biotechnol 35:185-97. 2007
    ..The advantages and disadvantages of the specific assays are discussed. A summary of research questions related to chemosensitivity testing is also included...
  4. ncbi Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers
    Rosalyn D Blumenthal
    Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ 07109, USA
    BMC Cancer 7:2. 2007
    ..Here, we compare both antigens as a function of histological phenotype in breast, pancreatic, lung, ovarian, and prostatic cancers, including patient-matched normal, primary tumor, and metastatic breast and colonic cancer specimens...
  5. ncbi Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (Carcinoembryonic Antigen)
    Rosalyn D Blumenthal
    Center for Molecular Medicine and Immunology, Garden State Cancer Center, Belleville, New Jersey 07109, USA
    Cancer Res 65:8809-17. 2005
    ..Thus, blocking the N and A1B1 domains of CEACAM5/CEACAM6 can impede the metastatic process...
  6. ncbi Abnormal expression of the angiopoietins and Tie receptors in menorrhagic endometrium
    Rosalyn D Blumenthal
    Garden State Cancer Center, Belleville, New Jersey 07109, USA
    Fertil Steril 78:1294-300. 2002
    ..To identify changes in expression of stimulatory and inhibitory factors when normal endometrium becomes menorrhagic...
  7. ncbi Tumor-specific dose scheduling of bimodal radioimmunotherapy and chemotherapy
    R D Blumenthal
    Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ 07109, USA
    Anticancer Res 23:4613-9. 2003
    ..We postulated that the agents and dose scheduling of bimodal RAIT plus chemotherapy might have to be tailored to each tumor based on the expression of specific relevant genes...
  8. ncbi An in vitro model to optimize dose scheduling of multimodal radioimmunotherapy and chemotherapy: effects of p53 expression
    Rosalyn D Blumenthal
    Garden State Cancer Center, Belleville, NJ 07109, USA
    Int J Cancer 108:293-300. 2004
    ....
  9. ncbi Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer
    Thomas M Cardillo
    The Garden State Cancer Center, 520 Belleville Avenue, Belleville, NJ 07109, USA
    Int J Cancer 97:386-92. 2002
    ..Our data show that combined gemcitabine with radioimmunotherapy may provide an improved alternative for the treatment of pancreatic cancer, achieving successful anti-tumor effects with low toxicity...
  10. ncbi Advantage of combining NLCQ-1 (NSC 709257) with radiation in treatment of human head and neck xenografts
    Maria V Papadopoulou
    Department of Radiation Medicine, Evanston Northwestern Healthcare, Evanston, Illinois 60201, USA
    Radiat Res 168:65-71. 2007
    ..These results suggest a significant advantage in combining radiation with NLCQ-1 in treatment of human head and neck tumors, which are known to have hypoxic areas...
  11. ncbi Altered tumor vessel maturation and proliferation in placenta growth factor-producing tumors: potential relationship to post-therapy tumor angiogenesis and recurrence
    Alice P Taylor
    Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ, USA
    Int J Cancer 105:158-64. 2003
    ..Prevention of this angiogenic response to treatment may require administration of anti-angiogenic therapy during, rather than after, treatment...
  12. ncbi Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients
    Jeffry A Siegel
    Nuclear Physics Enterprises, Cherry Hill, New Jersey 08003, USA
    J Nucl Med 44:67-76. 2003
    ....
  13. ncbi Modulation of marrow proliferation and chemosensitivity by tumor-produced cytokines from syngeneic pancreatic tumor lines
    Rosalyn D Blumenthal
    Garden State Cancer Center, Belleville, New Jersey 07109, USA
    Clin Cancer Res 8:1301-9. 2002
    ..We postulate that an excess of tumor-produced stimulatory or inhibitory cytokines could impact marrow proliferation and sensitivity to cytotoxic agents...
  14. ncbi Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft
    Rosalyn D Blumenthal
    Center for Molecular Medicine and Immunology, Garden State Cancer Center, 520 Belleville Avenue, Belleville, NJ 07109, USA
    Cancer Immunol Immunother 54:315-27. 2005
    ..The MAb also shows chemosensitizing properties...
  15. ncbi Sphingomyelin enhances chemotherapy efficacy and increases apoptosis in human colonic tumor xenografts
    David E Modrak
    Garden State Cancer Center, Belleville, NJ 07109, USA
    Int J Oncol 20:379-84. 2002
    ..Furthermore, this enhancement may be due to a reversal of the attenuation of the apoptotic signal found in cancer cells without inducing significant hematopoietic, hepatic or renal toxicity...
  16. ncbi Tumor-specific regulation of angiogenic growth factors and their receptors during recovery from cytotoxic therapy
    Alice P Taylor
    Tumor Biology, Garden State Cancer Center, Belleville, New Jersey 07109, USA
    Clin Cancer Res 8:1213-22. 2002
    ..Antiangiogenic therapy may require a tumor-specific combination of inhibitors for PlGF, the angiopoietins, or their receptors, in addition to VEGF/flk-1...
  17. ncbi Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines
    Chris Waskewich
    Garden State Cancer Center, Belleville, New Jersey 07109, USA
    Cancer Res 62:2029-33. 2002
    ....
  18. ncbi Peroxisome proliferator-activated receptor-gamma antagonists exhibit potent antiproliferative effects versus many hematopoietic and epithelial cancer cell lines
    Jack D Burton
    Center for Molecular Medicine and Immunology, Belleville, New Jersey 07109, USA
    Anticancer Drugs 18:525-34. 2007
    ..These findings support further translational studies to explore the mechanism of action and therapeutic potential of this class of agents...
  19. ncbi An overview of chemosensitivity testing
    Rosalyn D Blumenthal
    Garden State Cancer Center, Belleville, NJ, USA
    Methods Mol Med 110:3-18. 2005
    ..The advantages and disadvantages of the specific assays are discussed. A summary of research areas related to chemo sensitivity testing is also included...
  20. ncbi Tumor pO2 assessments in human xenograft tumors measured by EPR oximetry: location of paramagnetic materials
    Rosalyn D Blumenthal
    Department of Diagnostic Radiology, Dartmouth Medical School, Hanover, NH, USA
    Adv Exp Med Biol 530:205-14. 2003
    ..We monitored tumor pO2 during growth and also examined the tumor histological structure overall and in the region of the paramagnetic material in the tumor at the time of necropsy...

Research Grants3

  1. PRE-CLINICAL COMBINATION CHEMO- AND RADIOANTIBODY THERAP
    Rosalyn Blumenthal; Fiscal Year: 2004
    ..2) Therapy-induced changes in marker expression post therapy can be identified clinically in small samples of circulating tumor cells. ..